World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
64114
World Ranking
7495
National Ranking
288

Overview

Christian U. Blank is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands and has contributed extensively to research primarily within the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their work spans several subfields including Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Cancer Research.

Their research focuses on key topics such as Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Brain Metastases and Treatment, and Ocular Oncology and Treatments.

Christian U. Blank's frequent co-authors include:

  • John B.A.G. Haanen
  • Georgina V. Long
  • Ellen Kapiteijn
  • Karijn P.M. Suijkerbuijk
  • Geke A.P. Hospers

Their publications are regularly featured in venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Nature Medicine
  • Journal for ImmunoTherapy of Cancer

Some of the recent papers by Christian U. Blank include:

  • "B cells and tertiary lymphoid structures promote immunotherapy response," 2020, Nature
  • "The human tumor microbiome is composed of tumor type-specific intracellular bacteria," 2020, Science
  • "Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma," 2022, New England Journal of Medicine
  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology
  • "Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)," 2021, Nature Medicine

The breadth and focus of their work illustrate a sustained engagement with both clinical and molecular aspects of cancer research and immunotherapy, especially concerning melanoma and immune system interactions.

Best Publications

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

    Almut Brand;Katrin Singer;Gudrun E. Koehl;Marlene Kolitzus

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    Deborah Nejman;Ilana Livyatan;Garold Fuks;Nancy Gavert

  • Defining ‘T cell exhaustion’

    Christian U Blank;W Nicholas Haining;Werner Held;Patrick G Hogan;Patrick G Hogan

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

    Hanjie Li;Anne M. van der Leun;Ido Yofe;Yaniv Lubling

  • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    David Liu;David Liu;Bastian Schilling;Bastian Schilling;Derek Liu;Derek Liu;Antje Sucker

  • PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

    Christian Blank;Ian Elliott Brown;Amy C. Peterson;Mike Spiotto

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Chong Sun;Liqin Wang;Sidong Huang;Guus J. J. E. Heynen

  • Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

    Christian Blank;Thomas F. Gajewski;Andreas Mackensen

  • The “cancer immunogram”

    Christian U. Blank;John B. Haanen;Antoni Ribas;Ton N. Schumacher

  • MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

    Paolo A. Ascierto;Dirk Schadendorf;Carola Berking;Sanjiv S. Agarwala

  • Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

    Leonie Voorwerk;Maarten Slagter;Hugo M. Horlings;Karolina Sikorska

  • Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Christian U. Blank;Elisa A. Rozeman;Lorenzo F. Fanchi;Karolina Sikorska

Frequent Co-Authors

John B. A. G. Haanen
John B. A. G. Haanen Antoni van Leeuwenhoek Hospital
Georgina V. Long
Georgina V. Long University of Sydney
Ton N. M. Schumacher
Ton N. M. Schumacher Antoni van Leeuwenhoek Hospital
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Caroline Robert
Caroline Robert University of Paris-Saclay
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, you may also be interested in flexible online nursing programs that support diverse career goals. These options can help you gain qualifications without sacrificing work or personal commitments.

Many working nurses look for online rn to bsn programs without clinicals, which let you advance your education conveniently while avoiding additional clinical requirements. For those aiming for advanced practice roles, pursuing a 1 year dnp program online is a fast-track option to earn a terminal nursing degree quickly.

If you value flexibility and manageable coursework, exploring easiest online dnp programs could help meet your career ambitions with less stress. Alternatively, those who want to start working in healthcare sooner might consider a 6 month lpn program for rapid entry into the field.

Each of these pathways has unique benefits and challenges, so it’s important to research which program best matches your educational background and career objectives.

Best Scientists Citing Christian U. Blank

Trending Scientists